Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation

2019

Background & Aims Alpha-1 antitrypsin deficiency (AATD) is among the most common genetic disorders. Severe AATD is caused by a homozygous mutation in the SERPINA1 gene that encodes the Glu342Lys substitution (called the Pi*Z mutation, Pi*ZZ genotype). Pi*ZZ carriers may develop lung and liver diseases. Mutation-associated lung disorders have been well studied, but less is known about the effects in liver. We assessed the liver disease burden and associated features in adults with this form of AATD. Methods We collected data from 554 Pi*ZZ adults (403 in an exploratory cohort, 151 in a confirmatory cohort), in 9 European countries, with AATD who were homozygous for the Pi*Z mutation, and 234…

Liver CirrhosisMale0301 basic medicineALTLiver diseasechemistry.chemical_compound0302 clinical medicineLiver Function TestsRisk FactorsGenotypeRare Liver DiseaseAlpha 1-antitrypsin deficiencyHomozygoteAge FactorsGastroenterologyMiddle AgedEuropeEditorial CommentaryPhenotypemedicine.anatomical_structureLiverElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyTEAdultmedicine.medical_specialty610Mice Transgenic03 medical and health sciencesSex Factorsalpha 1-Antitrypsin DeficiencyInternal medicinemedicinePiAnimalsHumansGenetic Predisposition to DiseaseASTAgedLungHepatologyTriglyceridebusiness.industryLipid Metabolismmedicine.diseaseFatty Liver030104 developmental biologyEndocrinologychemistryCase-Control Studiesalpha 1-AntitrypsinMutationSteatosisTransient elastographybusinessGastroenterology
researchProduct

Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis

2016

AIM. To evaluate the effects of asymmetric dimethylarginine (ADMA) in renal arteries from portal hypertensive and cirrhotic rats. METHODS. Rat renal arteries from Sham (n = 15), pre-hepatic portal hypertension (PPVL; n = 15) and bile duct ligation and excision-induced cirrhosis (BDL; n = 15) were precontracted with norepinephrine, and additional contractions were induced with ADMA (10-6-10-3 mol/L), an endogenous inhibitor of nitric oxide (NO) synthase. Concentration-response curves to acetylcholine (1 × 10-9-3 × 10-6 mol/L) were determined in precontracted renal artery segments with norepinephrine in the absence and in the presence of ADMA. Kidneys were collected to determine the protein e…

Liver CirrhosisMale0301 basic medicineAsymmetric dimethylarginineCirrhosisArginineKidneyurologic and male genital diseasesRats Sprague-DawleyNorepinephrinechemistry.chemical_compoundRenal ArteryVasoconstrictor AgentsEnzyme InhibitorsPortal hypertensionKidneyGastroenterologyGeneral MedicineBasic StudyDimethylarginine dimethylaminohydrolaseNG-Nitroarginine Methyl Estermedicine.anatomical_structureCirrhosisCardiologyPortal hypertensionmedicine.symptommedicine.medical_specialtyCirrosi hepàticaEndotheliumArginineNitric OxidePressió sanguíniaAmidohydrolases03 medical and health sciencesInternal medicinemedicine.arteryHypertension PortalmedicineAnimalsHumansEndotheliumRenal arterybusiness.industrymedicine.diseaseAcetylcholineRats030104 developmental biologychemistryVasoconstrictionNitric oxide inhibitorsNitric Oxide SynthaseAsymmetric dimethylargininebusinessVasoconstriction
researchProduct

qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Ste…

2020

[Background and Aims] Nonalcoholic steatohepatitis (NASH) is a common cause of chronic liver disease. Clinical trials use the NASH Clinical Research Network (CRN) system for semiquantitative histological assessment of disease severity. Interobserver variability may hamper histological assessment, and diagnostic consensus is not always achieved. We evaluate a second harmonic generation/two‐photon excitation fluorescence (SHG/TPEF) imaging‐based tool to provide an automated quantitative assessment of histological features pertinent to NASH.

Liver CirrhosisMale0301 basic medicineBiopsyChronic liver diseaseSeverity of Illness IndexGastroenterologyHepatitis0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisNonalcoholic fatty liver diseaseqFibrosisNASH; automated; qFIBS; qFibrosis; quantitative evaluationNASH FIBROSISmedicine.diagnostic_testNASHMiddle AgedReference Standards3. Good healthLiverDimensional Measurement AccuracyLiver biopsyFemale030211 gastroenterology & hepatologyAlgorithmsmedicine.medical_specialtydigestive systemWhite People03 medical and health sciencesAsian PeopleInternal medicineImage Interpretation Computer-AssistedSeverity of illnessmedicineHumansqFIBSHepatologyReceiver operating characteristicbusiness.industryReproducibility of Resultsmedicine.diseasequantitative evaluationdigestive system diseasesConfidence intervalFatty Liver030104 developmental biologyautomatedSteatosisbusinessHepatology
researchProduct

Transformation of primary human hepatocytes in hepatocellular carcinoma

2015

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Currently, there is limited knowledge of neoplastic transformation of hepatocytes in HCC. In clinical practice, the high rate of HCC local recurrence suggests the presence of different hepatocyte populations within the liver and particularly in the tumor proximity. The present study investigated primary human hepatocyte cultures obtained from liver specimens of patients affected by cirrhosis and HCC, their proliferation and transformation. Liver samples were obtained from seven HCC cirrhotic patients and from three patients with normal liver (NL). Immediately after surgery, cell outgrowth and primary cultures were obtai…

Liver CirrhosisMale0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyCarcinoma HepatocellularCirrhosisGlypican 3Lesion03 medical and health sciences0302 clinical medicineGlypicansAntigens NeoplasmCell MovementSettore BIO/10 - BiochimicamedicineCarcinomaHumansNeoplasm InvasivenessNeoplastic transformationAgedCell ProliferationArginasebiologySettore BIO/16 - Anatomia UmanaLiver NeoplasmsCD44Hepatocellular CarcinomaMiddle AgedFlow Cytometrymedicine.diseaseImmunohistochemistrydigestive system diseasesCell Transformation NeoplasticHyaluronan Receptors030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisHepatocellular carcinomaHepatocyteHepatocytesbiology.proteinFemalemedicine.symptomInternational Journal of Oncology
researchProduct

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

2016

Background & Aims Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver damage and is characterized by steatosis. Genetic factors increase risk for progressive NAFLD. A genome-wide association study showed that the rs641738 C>T variant in the locus that contains the membrane bound O-acyltransferase domain-containing 7 gene (MBOAT7, also called LPIAT1) and transmembrane channel-like 4 gene (TMC4) increased the risk for cirrhosis in alcohol abusers. We investigated whether the MBOAT7-TMC4 is a susceptibility locus for the development and progression of NAFLD. Methods We genotyped rs641738 in DNA collected from 3854 participants from the Dallas Heart Study (a multi-ethnic…

Liver CirrhosisMale0301 basic medicineCirrhosisBiopsyProton Magnetic Resonance SpectroscopyPhosphatidylinositolsTriglycerideSeverity of Illness IndexGastroenterologyLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseMembrane Proteineducation.field_of_studyArachidonic Acidmedicine.diagnostic_testNASHGastroenterologyTexasEuropePhenotypeLiverLiver biopsyFemale030211 gastroenterology & hepatologyTexaCase-Control StudiePhosphatidylinositolHumanmedicine.medical_specialtyAcyltransferaseLiver CirrhosiEuropean Continental Ancestry GroupPopulationTM6SF2White PeopleArticle03 medical and health sciencesArachidonic Acid; NASH; PNPLA3; TM6SF2; Acetyltransferases; Acyltransferases; Biopsy; Case-Control Studies; Cross-Sectional Studies; Europe; European Continental Ancestry Group; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Liver; Liver Cirrhosis; Male; Membrane Proteins; Non-alcoholic Fatty Liver Disease; Phenotype; Phosphatidylinositols; Proton Magnetic Resonance Spectroscopy; Risk Factors; Severity of Illness Index; Texas; Triglycerides; Polymorphism GeneticGeneticAcetyltransferasesInternal medicineAcetyltransferasemedicineHumansGenetic Predisposition to DiseasePolymorphismeducationPNPLA3TriglyceridesCross-Sectional StudiePolymorphism GeneticHepatologybusiness.industryRisk FactorCase-control studyMembrane Proteinsmedicine.diseaseCross-Sectional Studies030104 developmental biologyEndocrinologyCase-Control StudiesSteatosisbusinessAcyltransferasesGenome-Wide Association StudyTM6SF2Gastroenterology
researchProduct

Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre…

2020

Background and aims: HCV is associated with an increased risk of cardiovascular events (CV). Whether HCV clearance by direct-acting antivirals (DAA) reduces incident CV disease is poorly understood. We investigate whether HCV eradication reduces CV events. Methods: In a prospective multicentre study, 2204 HCV patients (F0–F2:29.5%, F3–F4: 70.5%) were enrolled. Males were 48%, median age was 68 (59–74) years and BMI 25.9 (23.1–28); 24.7% were smokers, 18% had diabetes, 13.2% had cholesterol levels >200 mg/dl and 9.1% took statins, 44% had hypertension. During an overall median follow-up of 28 (24–39) months, incident CV events, such as ischemic heart disease (IHD) and ischemic cerebral st…

Liver CirrhosisMale0301 basic medicineCirrhosisMyocardial IschemiaComorbidityHepacivirusDisease030204 cardiovascular system & hematologyChronic hepatitis Cmedicine.disease_causechemistry.chemical_compound0302 clinical medicineRisk FactorsProspective StudiesIschemic heart disease Ischemic cerebral stroke Chronic hepatitis C CirrhosisIncidenceIncidence (epidemiology)SmokingMiddle AgedViral LoadStrokeItalyHypertensionFemaleCardiology and Cardiovascular MedicineDirect actingmedicine.medical_specialtyIschemic heart diseaseHepatitis C virusHypercholesterolemiaAntiviral Agents03 medical and health sciencesDiabetes mellitusInternal medicineDiabetes MellitusmedicineHumansViremiaAgedCirrhosibusiness.industryCholesterolHepatitis C Chronicmedicine.disease030104 developmental biologychemistryRelative riskIschemic cerebral strokeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessAtherosclerosis
researchProduct

Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Dis…

2017

Context Contrasting data have been reported on the role of irisin, a novel myokine encoded by the fibronectin type III domain-containing protein 5 (FNDC5) gene, in nonalcoholic fatty liver disease (NAFLD) pathogenesis. We tested in patients with suspected nonalcoholic steatohepatitis (NASH) the association of FNDC5 variants, hepatic expression, and circulating irisin with liver damage (F2 to F4 fibrosis as main outcome). We also investigated whether irisin modulates hepatocellular fat accumulation and stellate cell activation in experimental models. Methods We considered 593 consecutive patients who underwent liver biopsy for suspected NASH and 192 patients with normal liver enzymes and wit…

Liver CirrhosisMale0301 basic medicineEndocrinology Diabetes and MetabolismClinical BiochemistrySeverity of Illness IndexBiochemistryGastroenterologyMiceEndocrinologyNon-alcoholic Fatty Liver DiseaseFibrosisNonalcoholic fatty liver diseaseOdds RatioProspective StudiesCarbon Tetrachloridemedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionHep G2 CellsMiddle AgedFNDC5LiverLiver biopsyFemaleAdultmedicine.medical_specialtyIn Vitro TechniquesDiet High-FatReal-Time Polymerase Chain ReactionPolymorphism Single Nucleotide03 medical and health sciencesDiabetes mellitusInternal medicineMyokineHepatic Stellate CellsmedicineAnimalsHumansFNDC5 IRISIN NAFLDGenetic Predisposition to Diseasebusiness.industryBiochemistry (medical)medicine.diseasedigestive system diseasesFibronectins030104 developmental biologyEndocrinologyCase-Control StudiesHepatic stellate cellSteatosisbusinessThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Association between MICA Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample

2018

There are currently no biomarkers that predict hepatocellular carcinoma (HCC) risk in patients with hepatitis C virus (HCV)-related cirrhosis. We investigated the relationships among major histocompatibility complex (MHC) class I chain-related gene A (MICA) polymorphisms, plasma levels of soluble MICA (sMICA), and HCC risk in patients with HCV-related HCC. One hundred fifty-four HCV-related HCC patients, 93 HCV-related liver cirrhosis (LC) cases, and 244 healthy controls, all sampled from the native Sicilian population, were genotyped using the KASP™ single-nucleotide polymorphism genotyping method. The MICA rs2596542 polymorphism showed that the G/G genotype was significantly more frequent…

Liver CirrhosisMale0301 basic medicineGenetic LinkageHepacivirusHepacivirusmedicine.disease_causeGastroenterologyBiochemistryLinkage DisequilibriumMiceLiver disease0302 clinical medicineGenotypeOdds RatioAged 80 and overeducation.field_of_studybiologyHepatitis Chepatocellular carcinomaMiddle AgedHepatitis CItalyPopulation Surveillance030220 oncology & carcinogenesisHepatocellular carcinomagenetic association studyHCVMolecular MedicineFemaleDisease SusceptibilityCell-Free Nucleic AcidsBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusPopulation03 medical and health sciencesInternal medicinemedicineGeneticsAnimalsHumanseducationMolecular BiologyAllelesAgedbusiness.industryliver cirrhosiDecision TreesHistocompatibility Antigens Class IGenetic VariationOdds ratiomedicine.diseasebiology.organism_classificationdigestive system diseases030104 developmental biologyMICAbusinessBiomarkers
researchProduct

MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease

2015

Background & Aim Homozygosity for a common non-coding rs4374383 G>A polymorphism in MERTK (myeloid-epithelial-reproductive tyrosine kinase) has been associated with the protection against fibrosis progression in chronic hepatitis C. The main study objective was to assess whether MERTK AA genotype influences liver fibrosis, and secondarily MERTK expression in patients with non-alcoholic fatty liver disease (NAFLD). We also investigated whether MERTK is expressed in human hepatic stellate cells (HSC) and in murine models of fibrogenesis. Methods We considered 533 consecutive patients who underwent liver biopsy for suspected non-alcoholic steatohepatitis (NASH) without severe obesity from two …

Liver CirrhosisMale0301 basic medicineMessengerMice0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInbred BALB CCells CulturedMice Inbred BALB CCulturedmedicine.diagnostic_testMedicine (all)Fatty liverNASHMiddle AgedLiver biopsyFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyMERTKCellsBiology03 medical and health sciencesGeneticProto-Oncogene ProteinsInternal medicinemedicineAnimalsHumansFibrosis; MERTK; NASH; Adult; Animals; Cells Cultured; Female; Humans; Liver Cirrhosis; Male; Mice Inbred BALB C; Middle Aged; Non-alcoholic Fatty Liver Disease; Proto-Oncogene Proteins; RNA Messenger; Receptor Protein-Tyrosine Kinases; Polymorphism Genetic; Medicine (all); HepatologyRNA MessengerPolymorphismPolymorphism Geneticc-Mer Tyrosine KinaseHepatologyGAS6Receptor Protein-Tyrosine Kinasesnafld fibrosis mertkMERTKHepatologymedicine.diseaseFibrosis030104 developmental biologyImmunologyHepatic stellate cellRNASteatohepatitisJournal of Hepatology
researchProduct

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential an…

2016

There are no approved treatments for liver fibrosis. To aid development of antifibrotic therapies, noninvasive biomarkers that can identify patients with progressive fibrosis and that permit monitoring of the response to antifibrotic therapy are much needed. Samples from a phase II antifibrotic trial of the glitazone farglitazar in patients with advanced hepatitis C, with matched follow-up liver biopsies, and from a phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) were analyzed for serological Pro-C3 levels in conjunction with other disease parameters. In the farglitazar study, a predefined cutoff value for Pro-C3 as a selection criterion led to t…

Liver CirrhosisMale0301 basic medicineNonalcoholic steatohepatitisPathologymedicine.medical_specialtyPhysiologyLiver fibrosisType 2 diabetesSerology03 medical and health sciencesCollagen formation0302 clinical medicineFibrosisSerum biomarkersPhysiology (medical)Journal ArticlemedicineHumansOxazolesType III collagenHepatologybusiness.industryPatient SelectionGastroenterologyMiddle Agedmedicine.disease3. Good healthCollagen Type III030104 developmental biologyQuinazolinesTyrosineFemaleThiazolidinediones030211 gastroenterology & hepatologybusinessBiomarkersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct